Our clients
Accelerate your antibody discovery research, enhance precision, and secure your innovations with Isogenica’s tailor-made solutions.
Unmatched diversity
Accelerate your antibody discovery research with access to the world’s largest synthetic VHH libraries
With the world’s largest synthetic VHH libraries, Isogenica offers unparalleled diversity in antibody discovery. This extensive collection ensures that our clients have access to a broad spectrum of high-affinity antibodies, increasing the chances of finding the perfect match for your therapeutic or diagnostic needs.
Working with us
Risk reduction for long-term success
Our focus on risk reduction, coupled with our proven track record, makes us a reliable partner for those navigating complex development challenges. Isogenica’s solutions not only reduce development timelines but also enhance the likelihood of success by securing robust intellectual property early in the process.
Discovery Terms: Clear, Collaborative, and Built for Scientists
At Isogenica, we offer a transparent and flexible discovery model designed to support your scientific and commercial goals at every stage:
Panning & Screening
Following an initial screening phase (typically 4–6 weeks), up to 100 Deliverable Antibody sequences are shared for your evaluation. Project-specific data can also be provided to help guide sequence selection.
Characterisation & Evaluation
From this set, up to five Selected Antibodies may be identified for further development. Characterisation and assay work can be carried out by Isogenica, by your team, or jointly. Non-selected Deliverable Antibodies are returned to Isogenica’s library at the end of the evaluation period. A 12-month evaluation window begins upon delivery of the final project report.
Final Deliverables & Licensing
You will receive an exclusive license to the five Selected Antibodies. This license grants you full rights to develop, optimise, patent, publish, and commercialise each candidate. While these antibodies remain physically present in Isogenica’s libraries, they are digitally withdrawn and will not be shared or licensed to any other party, including internally at Isogenica.
Our commercial model is Fee-for-Service. No milestones, royalties, or success fees apply.
Start your discovery with us
We tailor our approach to fit your unique project. Options include fee-for-service contracts, rolling FTE models, or success-based milestones. Each client’s needs determine the best model for collaboration.
It’s been a pleasure working with the Isogenica team. The regular project updates and open discussions ensured that together we could overcome the challenges presented by the biology of the targets and maximized our chances of success.
Clients and case studies
We have an ongoing research programme with AstraZeneca. The partnership centres around the use of our CIS display technology for the discovery of peptides which are specific for, and biologically active against, targets provided by AstraZeneca. Read more here and find out about an example target, phospholamban.
Teaming up with Aro, we’re working with them using our CIS display to identify and characterise novel Centyrins™ against target antigens. Read more.
Our partnership with WellmarkerBio and Isogenica involves the research and development of antibody-based cancer immunotherapy, Protein-Protein Interaction (PPI) Inhibitors, biomarkers and peptide libraries. Read more.
Our partnership with Takeda sees them use our family of VHH single-domain antibody libraries for the discovery, development and commercialisation of therapeutic products. Read more.
Our multi-project contract is aiming to develop molecules that can be used in clinical laboratory assays to measure biomarkers correlated with the molecular effectiveness of cancer immuno-oncology agents. Read more.
We’ve teamed up with Arvinas who are leveraging our CIS display technology in support of advancing and expanding their PROTAC® platform. Read more.
Partnerships at Isogenica
Despite the confidentiality of our clients, Isogenica consistently receives high satisfaction ratings, with 100% of VHH discovery customers rating between 8 and 10/10 on how likely they would be to recommend our organization to a friend or colleague. Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including three clinical-stage assets (Phase I and Phase II) and dozens of partnered pre-clinical and discovery programs. Contact us to find out how to revolutionise your research and development with VHH antibody technologies.